Abstract P1-03-07: Investigation of combination treatment an aromatase inhibitor and anti-inflammatory treatment in a model of oestrogen receptor positive breast cancer

摘要: Background: Previous analysis has revealed that high pre-treatment expression of an inflammatory gene signature and lymphocytic infiltration are correlated with poor response to neoadjuvant aromatase inhibitor (AI) treatment1. Upon treatment AIs, also increases1. These changes seen in vitro where increase chemokine secretion been observed upon oestrogen deprivation, suggesting anti-oestrogen therapy may modulate the immune response. In addition, non-steroidal anti-inflammatory drug (NSAID) intake is associated a significantly decreased risk disease recurrence breast cancer related death. this study we set out investigate immunological AI alone combination NSAID animal model estrogen receptor positive (ER+ve) cancer. Methods: A syngeneic immunocompetent murine ER+ tumour was used which SSM3 BrCa cells were injected into mammary pad wild-type 129SvEv mice. Once tumours reached size 49 mm2, mice ovariectomised treated combinations letrozole, celecoxib, aspirin vehicle control. Tumours measured for 25 days following analysed using flow cytometry immunohistochemistry. Results: Treatment letrozole + celecoxib resulted significant reduction after (p